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Cas9 is an RNA-guided endonuclease that specifically binds and cleaves DNA with complementarity to the spacer sequence of CRISPR RNA (crRNA) located upstream of 
a protospacer adjacent motif (PAM)1,2. Sufficient base pairing of 
the crRNA spacer of either dual-RNA (trans-activating crRNA 
(tracrRNA) in complex with crRNA) or single-guide RNA (sgRNA, 
tracrRNA fused to crRNA) with the target DNA strand leads to 
displacement of the nontarget strand and R-loop formation1–5. 
On completion of this process, Cas9 endonuclease domains, HNH 
and RuvC, cleave the target and nontarget strand, respectively, 
resulting in a double-strand DNA break1,2. Due to its program-
mability, CRISPR-Cas9 was adapted for a wide variety of genome 
engineering approaches6–9. However, a main concern for the appli-
cation of the CRISPR-Cas9 technology is off-target cleavage that 
occurs when Cas9 cleaves mismatched targets; that is, targets 
with imperfect complementarity to the dual-RNA/sgRNA spacer. It 
is therefore crucial to identify regions and amino acids that deter-
mine Cas9 specificity.
Streptococcus pyogenes Cas9 (SpCas9) requires a seed sequence of 
10–12 base pairs (bp) adjacent to the PAM for successful cleavage2. 
The REC3 domain senses PAM-distal mismatches and controls the 
transition of the HNH domain into an active conformation, which 
serves as a mechanism to block the cleavage in the presence of mis-
matches10,11. Alongside other strategies to reduce off-target cleav-
age12, both structure-guided and random mutagenesis have been 
used to generate enhanced specificity Cas9 variants10,13–19. Three 
of the improved variants10,15,17 contain mutations that increase the 
energetic barrier for transition of the HNH domain to the cleav-
age-competent state10. eSpCas9 (ref. 17) and SpCas9-HF1 (ref. 15) 
require one additional base pair between crRNA and target DNA 
for stable binding, which makes target unwinding more sensitive to 
mismatches and slows cleavage in the presence of mismatches20. 
It was shown that mutation of two residues in the loop region of the 
bridge helix impairs target cleavage and improves specificity21. The 
conformational checkpoint through the HNH domain before cleav-
age and the seed sequence are the only known specificity determi-
nants for Cas9. In addition, stable R-loop formation is an essential 
prerequisite for cleavage5, but residues involved in this process have 
not been identified. Therefore, we investigated whether other Cas9 
domains are involved in mismatch sensing and R-loop stabilization 
focusing on the PAM-adjacent region of the target.
We show that arginines of the Cas9 bridge helix influence guide 
RNA binding, and target DNA binding and cleavage. We identify 
two groups of arginines with opposite effects on Cas9 mismatch 
sensitivity. We demonstrate that R63, R66 and R70 stabilize the 
R-loop in the presence of PAM-adjacent mismatches thus reducing 
the Cas9 specificity. Additionally, we observe that Q768 mediates 
Cas9 insensitivity to a mismatch in target position 15 and is involved 
in sensitivity to PAM-distal mismatches. Combination of R63 and 
Q768 exchanges to alanine increased Cas9 sensitivity to mismatches 
in vitro, in bacteria and human cells. Our results elucidate the basis 
for Cas9-mediated sensing of PAM-adjacent mismatches and estab-
lish a framework to further improve the specificity of Cas9 for 
genome engineering applications.
Results
Influence of mismatches on binding and cleavage by Cas9. We 
wanted to determine how mismatches between crRNA and target 
DNA influence the binding and cleavage by Cas9. Therefore, we 
performed in vitro binding and kinetic cleavage assays to determine 
the binding constants and cleavage rates of SpCas9 on the proto-
spacer 2 (speM superantigen) target sequence3 (Fig. 1a). We also 
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investigated the influence of mismatches on cleavage by Cas9 in vivo 
in E. coli, where the target sequence is located within rfp on a plasmid 
(Methods and Supplementary Figs. 1 and 2a). Single mutations were 
introduced in each position of the target sequence (in vitro) (Fig. 1a) 
or the sgRNA (in  vivo) (Supplementary Fig. 2a) to prevent base 
pairing between the crRNA and DNA at the corresponding posi-
tion. In the in vivo bacterial toxin–antitoxin survival assay, growth 
is a measure of Cas9 activity; that is, when Cas9 is active, bacterial 
cells are unable to propagate because Cas9 cleaved the reporter plas-
mid encoding the antitoxin, whereas bacteria can grow when Cas9 is 
unable to cleave (Methods and Supplementary Fig. 1).
A mismatch in the first two PAM-adjacent nucleotides negatively 
affected the binding of Cas9 to the DNA (Fig. 1b). Consequently, the 
cleavage rates for these two targets were reduced compared to that of 
the target fully complementary to the crRNA spacer (fully comple-
mentary, FC) (Fig. 1c). This demonstrates that Cas9 is sensitive to 
mismatches in the first two target positions, in agreement with pre-
vious studies5,22,23. Cas9 cleaves between the third and fourth base 
pair of the target2. The cleavage of substrates with mismatches at 
positions 3–5 was decreased, yet these substrates were bound with 
an affinity comparable to the one on FC substrate, indicating an 
impairment affecting only catalysis. Reduced cleavage rate in pres-
ence of a mismatch at position 6 is due to poorer binding of Cas9 
to this substrate (Fig. 1b). In contrast to the first six PAM-adjacent 
positions in vitro, complementarity at only four PAM-adjacent posi-
tions was important for cleavage in E. coli (Supplementary Fig. 2b). 
This discrepancy can be due to the different nucleotide sequences 
used, as the spacer sequence and the identity of the mismatch can 
influence the sensitivity to the mismatch24,25. Additionally, the dif-
ferences could be explained by the measured parameters; that is, 
cleavage rate in vitro and end-point for bacterial survival.
We observed that on substrates with mismatches in positions 
10–14, the rates for cleavage were different for each DNA strand 
(Fig. 1c), implying that one endonuclease domain was cleaving 
faster than the other. Cleavage assays on linear substrates demon-
strate that cleavage by the RuvC domain was slower (Supplementary 
Fig. 3). Substrates with mismatches in positions 17–20 were cleaved 
with reduced rates compared to the FC substrate, in line with pre-
vious studies demonstrating that a certain degree of PAM-distal 
complementarity is necessary for cleavage11,26,27.
Cas9 not only tolerated a mismatch in position 15, but displayed 
an enhanced cleavage rate (Fig. 1c). Bacteria in which Cas9-sgRNA 
C15G was expressed also showed reduced survival when compared 
to bacteria in which Cas9-sgRNA wild type (WT) was expressed, 
indicating that the effect is not sequence-dependent (Supplementary 
Fig. 2b). The same was detected when Streptococcus mutans Cas9 
was tested for in vitro cleavage of the substrate with mismatch 15 
(Supplementary Fig. 4).
Q768 is involved in sensitivity to PAM-distal mismatches. In an 
unrelated project, we analyzed a set of cas9 mutants that retained 
activity on the FC substrate. Exchange of Q768 to alanine resulted in 
a cleavage rate on substrate with a mismatch at position 15 that was 
comparable to the cleavage rate on FC substrate. Examination of 
the cocrystal structure of S. pyogenes Cas9 (ref. 28) revealed that the 
side-chain of Q768 is located at the border between RuvC and HNH 
domains and is in proximity to the DNA at position 15 (Fig. 2a). 
A mismatch might perturb the contact between Q768 and the 
RNA–DNA hybrid, and as a result affect the cleavage rate. To deter-
mine whether Q768 is responsible for this, we replaced it with glu-
tamate, asparagine or alanine, and assessed Cas9 activity in E. coli  
(Fig. 2b). Expression of these Cas9 variants resulted in survival 
comparable to bacteria where Cas9_wt was expressed. However, in 
the presence of the sgRNA C15G, Cas9_Q768A, Cas9_Q768E and 
Cas9_Q768N showed increased survival when compared to Cas9_wt, 





















































































































Fig. 1 | The influence of mismatches between the crRNa and target DNa 
on binding and cleavage by Cas9. a, Scheme of speM target site (purple) 
used in the in vitro assays. This protospacer corresponds to spacer 2, 
present in the type II-A CRISPR array of S. pyogenes SF370. Base pairing 
of the crRNA to the target strand is indicated (for reasons of clarity, 
crRNA is shown truncated and tracrRNA is not shown). Mutations were 
introduced in the DNA, leading to a mismatch between the crRNA spacer 
and the target DNA. The numbering of mismatches is indicated above 
the nontarget strand. The PAM is shown in green. b, Binding constants 
(KD) derived from EMSAs with increasing concentrations of Cas9_wt and 
two molar excess of dual-RNA on 90 bp 5′-32P labeled PCR products of 
the target sites used for kinetic cleavage assays. Binding constants were 
calculated as described in Methods. c, In vitro cleavage rates (kobs) obtained 
by kinetic cleavage assays with 5 nM plasmid DNA (containing wild-type 
or mutated target site) and 10 nM Cas9 in complex with 20 nM dual-RNA. 
Mutations along the target site are indicated on the x axis, starting from 
the first PAM-adjacent nucleotide. The cleavage rate k1obs (dark blue) 
represents disappearance of the supercoiled plasmid DNA, whereas the 
cleavage rate k2obs (light blue) represents appearance of the linear DNA. 
Cleavage rates were calculated as described in Methods. b,c, Binding 
constants and cleavage rates were calculated by concatenated fitting, 
represented are mean values. Error bars represent the standard deviation 
(s.d.) (n ≥ 3 independent experiments, Supplementary Table 1). FC, fully 
complementary target substrate.
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Cas9 in the presence of a mismatch on position 15. In vitro cleav-
age rates of Cas9_Q768A and Cas9_Q768E on the FC and T15A 
substrates were either in the same range or slightly slower on T15A, 
while for Cas9_Q768N the first cleavage rate was faster on T15A 
substrate compared to the FC substrate, although not to the same 




















































































































































Fig. 2 | Q768 is involved in Cas9 sensitivity to PaM-distal mismatches. a, Cocrystal structure of Cas9 bound to sgRNA (spacer in yellow, sgRNA scaffold 
in dark gray) and DNA target strand (purple) (Protein Data Bank accession no. 4OO8). HNH motif is shown in pink, RuvC in blue, bridge helix in green, 
recognition lobe in gray and C-terminal domain in beige. Q768 (orange) and DNA position 15 (dark blue) are zoomed in (dashed box). The distance 
between Q768 and position 15 is 20.3 Å. b, Bacterial survival assay with Cas9_wt, Cas9_Q768N, Cas9_Q768E and Cas9_Q768A, in the presence of WT 
or C15G sgRNAs. Survival represents the OD600 nm of induced versus suppressed expression of WT or mutant Cas9. c, In vitro cleavage rates of Cas9_wt 
and Q768 mutants on target DNA having a mismatch at position 15 normalized to the cleavage rate of each protein on the FC substrate. Cleavage rates 
(k1obs in dark blue and k2obs in light blue) were calculated as described in Methods using a concatenated fit, represented are mean values. Error bars 
represent normalized s.d. (n ≥ 3 independent experiments, Supplementary Table 1). d,e, Bacterial survival assay with Cas9_Q768A (d) and Cas9_Q768E 
(e), in the presence of WT and mismatched sgRNAs (labeled on x axis). The dotted line at 0.95 indicates the value obtained with dCas9 (catalytically 
inactive Cas9) that represents no cleavage. Statistical analysis of at least four replicates was performed with Origin Software. b,d,e, Boxes represent the 
interquartile range between 25th and 75th percentiles. The median and mean (n ≥ 4 independent experiments, Supplementary Table 2) are indicated by a 
horizontal line and the square, respectively. The whiskers show minimum and maximum.
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Since Q768 affects Cas9 sensitivity to a mismatch on position 15, 
its replacement with alanine or glutamate might also influence the 
sensitivity to other PAM-distal mismatches. Hence, we tested the 
activity of these Cas9 variants in E. coli with mismatched sgRNAs 
(Fig. 2d,e). The respective bacterial strains showed increased sur-
vival in presence of sgRNAs with mismatches in positions 13 and 
15–19 when compared to the WT sgRNA, and when compared to 
survival obtained with Cas9_wt. This indicates that these variants 
cleaved the target to a lesser extent than Cas9_wt in the presence of 
PAM-distal mismatches. We also noted that the sensitivity to PAM-
adjacent mismatches was decreased when compared to Cas9_wt 
(Supplementary Fig. 2b).
Bridge helix arginines affect Cas9 binding and cleavage. To 
explore whether other amino acids and/or domains influence 
Cas9 sensitivity to mismatches in the PAM-adjacent part of the 
target, we investigated the conserved arginine-rich bridge helix 
(Supplementary Fig. 5). The bridge helix of SpCas9 comprises eight 
arginine residues (R63, R66, R69, R70, R71, R74, R75, R78), which 
make contacts to the sgRNA phosphate backbone in the specificity-
determining seed region28–31 (Fig. 3a). We tested Cas9 variants of 
these arginine residues for binding to dual-RNA and target DNA, 
and cleavage of the FC target. All variants showed reduced in vitro 
cleavage rates when compared to Cas9_wt (Fig. 3b). Combination 
of these results with the data from binding assays (Fig. 3c,d) reveals 
three groups of mutants. First, Cas9_R66A, Cas9_R70A and 
Cas9_R74A have higher RNA binding constants than Cas9_wt 
(Fig. 3c), indicating that these residues are important for RNA bind-
ing, in agreement with the multiple contacts of these arginines to 
the sgRNA backbone28–31. Second, Cas9_R66A and Cas9_R71A are 
deficient in DNA binding (Fig. 3d), which in the case of Cas9_R66A 
might be due to its reduced RNA binding. For Cas9_R71A, how-
ever, the RNA binding affinity is not decreased indicating that R71 is 
directly involved in DNA binding. Possibly as a consequence of these 
binding deficiencies, the observed cleavage rates of Cas9_R66A, 
Cas9_R70A, Cas9_R71A and Cas9_R74A were slower when com-
pared to Cas9_wt. Slower cleavage rates were also observed for 














































































































Fig. 3 | arginine residues from the bridge helix affect DNa cleavage, RNa binding and target DNa binding by Cas9. a, Zoom in on the bridge helix  
(light green) and crRNA spacer (yellow) from Fig. 2a. The conserved arginines are shown in stick representation with dashed lines indicating hydrogen 
bonds or salt bridges to the crRNA (according to Nishimasu et al.28). R63, R66 and R70 are shown in orange; R69, R71, R74 and R78 in dark green and R75 
in light green. b, In vitro cleavage rates of Cas9_wt and arginine mutants obtained by kinetic cleavage assays using 5 nM plasmid DNA (containing the WT 
target site) and 10 nM Cas9 in complex with 20 nM dual-RNA. k1obs is shown in dark blue and k2obs in light blue. c, Binding constants (KD) of Cas9_wt and 
arginine mutants (Cas9_R63A, Cas9_R66A, Cas9_R69A, Cas9_R70A, Cas9_R71A, Cas9_R74A, Cas9_R75A and Cas9_R78A) derived from RNA-binding 
assays on dual-RNA, performed and calculated as described in Methods. Error bars represent the s.d. of at least three independent experiments. d, Binding 
constants resulting from EMSAs of Cas9_wt and arginine mutants on 90 bp 5′-32P labeled PCR product of the WT target site. b–d, Cleavage rates and 
binding constants were calculated by concatenated fitting, represented are mean values. Error bars represent the s.d. (n ≥ 3 independent experiments, 
Supplementary Tables 1 and 3).
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displayed RNA and DNA binding constants comparable to Cas9_wt, 
implying that these residues are important for catalysis. In E. coli, 
increased survival was observed only in the presence of Cas_R66A, 
Cas9_R70A and Cas9_R74A (Supplementary Fig. 6). Last, exchange 
of R75 slightly reduced the in vitro cleavage rate, but had no effect 
on RNA and DNA binding or survival in vivo.
Two sets of arginines with opposite effects on specificity. To study 
whether the arginines have an effect on Cas9’s sensitivity to mis-
matches, we exchanged them to alanine and tested these Cas9 variants 
for binding and cleavage of mismatched substrates in vitro, and in the 
bacterial survival assay with mismatched sgRNAs. Cleavage rates of 
Cas9_R75A on mismatched substrates (Fig. 4a and Supplementary 
Fig. 7g) and bacterial survival (Supplementary Fig. 8g) were like 
those of Cas9_wt. We identified two groups of mutants with oppo-
site effects on Cas9 mismatch sensitivity (Fig. 4a and Supplementary 
Figs. 7 and 8). First, Cas9_R69A, Cas9_R71A, Cas9_R74A and 
Cas9_R78A cleaved most mismatched substrates with a similar cleav-
age rate or faster than the FC substrate (Fig. 4a, dark blue and shades 
of gray). This indicates that R69, R71, R74 and R78 confer specific-
ity to Cas9 and changing them renders the protein less sensitive to 
mismatches; that is, the specificity decreases. Cas9_R78A tolerates 
a mismatch in position 4 in vivo (Supplementary Fig. 8h), whereas 
Cas9_wt and the remaining arginine variants are all highly sensitive 
to this mismatch (Supplementary Fig. 8a–g). R78 could be acting as 
a mismatch-sensing residue on target position 4. This is consistent 
with the Cas9 structure where R78 contacts the sgRNA nucleotides 
that base pair with the target DNA positions 3–4 (refs. 28–31).
The second group comprises Cas9_R63A, Cas9_R66A and 
Cas9_R70A. Cleavage rates of these variants on mismatched sub-
strates were similar to or slower than on FC substrate (Fig. 4a, 
shades of light blue and Supplementary Fig. 7a,b,d). This is par-
tially due to impaired binding of these mutants to several substrates 
containing a PAM-adjacent mismatch (Fig. 4b,c,d), indicating 
that replacing these residues renders Cas9 more sensitive to mis-
matches. Cas9_R70A was inactive in E. coli (Supplementary Fig. 6) 
consistent with a previous report in eukaryotic cells28. A possible 
explanation could be its reduced RNA binding (Fig. 3c). Hence, 
we focused on the remaining two variants, which displayed 
increased specificity.
Next, we wanted to determine whether changing both R63 






















































































































































Fig. 4 | Two groups of arginine residues with opposite effects on Cas9 sensitivity to mismatches. a, Heat map of in vitro cleavage rates of Cas9_wt and 
arginine mutants normalized to each protein’s rate on the FC substrate. Cleavage rates were determined as described in Methods from at least three 
independent experiments. Shades of blue (values less than 1) indicate that the cleavage rate is slower or similar to the cleavage rate on the WT substrate, 
whereas shades of gray (values more than 1) indicate that the cleavage rate is similar to or faster than the cleavage rate on the wt substrate. b–d, 
Binding constants of Cas9_R63A (b), Cas9_R66A (c) and Cas9_R70A (d) on the WT and mismatched substrates, determined by concatenated fitting, 
represented are mean values. Error bars represent the s.d. (n ≥ 3 independent experiments, Supplementary Table 1). Asterisks indicate that due to poor 
binding of the protein to the substrate, binding constants could not be determined with confidence under the tested conditions.
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Cas9_RR63,66AA was able to fully cleave the WT substrate in vitro, 
although slower than Cas9_wt (Supplementary Fig. 9a). Analysis 
of the cleaved supercoiled plasmid DNA (Supplementary Fig. 9b) 
revealed that Cas9_wt fully cleaved most of the substrate plas-
mids (indicated by 100% cleavage). In contrast, Cas9_RR63,66AA 
cleaved most of the plasmids with PAM-adjacent mismatches only 
up to 50%. This decrease in the amount of cleavage product is pos-
sibly due to poorer binding in the presence of a PAM-adjacent mis-
match, since we could only measure the binding constant for the 
FC substrate (Supplementary Fig. 9c). Bacterial survival in presence 
of Cas9_RR63,66AA and WT sgRNA was comparable to survival 
in presence of dCas9 (Supplementary Fig. 9d), indicating that this 
variant is inactive in vivo.
R63 and R66 stabilize the R-loop in presence of mismatches. 
A previous study indicated that the bridge helix might play a role in 
the initiation of R-loop formation32. Therefore, we examined argi-
nine variants for binding to DNA substrates, where five or twenty 
mismatches were introduced between the target and nontarget 
strand of the substrate resulting in unpaired DNA, mimicking a par-
tially or fully formed R-loop (Supplementary Fig. 10). Binding of 
the arginine variants on opened substrates was improved compared 
to the WT substrate, indicating that these Cas9 variants are involved 
in R-loop formation and/or stability (Fig. 5a).
This led us to hypothesize that R63, R66 and R70 render Cas9 
less specific by positively affecting the R-loop stability in the pres-

























































































































































































Fig. 5 | arginines 63, 66 and 70 stabilize the R-loop in the presence of mismatches. a, Binding constants derived from EMSAs of Cas9_wt and arginine 
mutants on 140 bp 5′-32P labeled oligonucleotides containing the NGG PAM and the target site without a bulge (target and nontarget strand fully base 
paired), a 5-nt bulge starting from the PAM-adjacent side of the target or with a complete 20-nt bulge (the scheme of the oligonucleotides can be found in 
Supplementary Fig. 10, whereas the full sequences of the oligonucleotides can be found in Supplementary Table 8). EMSAs were done as previously described, 
but in KG buffer instead of the Binding buffer. b–d, Binding constants of Cas9_wt (dark blue) and Cas9_R63A (light blue) (b), Cas9_wt (dark blue) and  
Cas9_R66A (light blue) (c), and Cas9_wt (dark blue) and Cas9_R70A (light blue) (d) on the different oligonucleotide substrates (with the target site indicated 
on the x axis). PAM is indicated in red, positions where the substrate is opened is shown as a bulge and a mismatch is marked by the blue asterisk. The black  
asterisks indicate that due to poor binding of the protein to the substrate, it was not possible to determine the KD with confidence. a–d, Binding constants were 
determined by concatenated fitting, represented are mean values. Error bars represent the s.d. (n ≥ 3 independent experiments, Supplementary Table 3).
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Cas9_R66A and Cas9_R70A on two sets of opened DNA substrates. 
The first set allowed full base pairing between the crRNA and DNA, 
but mismatches were introduced between the two DNA strands, 
resulting in a bulge. The second set contained a mismatch prevent-
ing base pairing of the crRNA and DNA at a specific position and 
were opened in the two subsequent positions to facilitate R-loop 
formation (Fig. 5b–d).
Cas9_R63A binds the FC substrate comparable to Cas9_wt 
(Fig. 3c), but has a binding defect on the substrate with mismatched 
position 8 (G8C) (Fig. 4b, note that the binding defect on A6T is 
also observed with Cas9_wt and therefore not related to the R63A 
exchange). This suggests that R63 stabilizes the R-loop in the pres-
ence of a mismatch on target position 8. On the other hand, if the 
substrate containing the G8C mismatch is opened at positions 9 and 
10 (G8C 9_10), Cas9_R63A binds with the same affinity as to the 
FC substrate (Fig. 5b), indicating that the negative effect of replac-
ing R63 is neutralized by opening the substrate and facilitating 
R-loop formation. This indicates that R63 stabilizes the R-loop in 
the presence of a mismatch on position 8 and thus could lower the 
sensitivity of Cas9 to this mismatch.
Cas9_R66A displayed binding defects on substrates contain-
ing mismatches on positions 3–9 (Fig. 4c). We tested this Cas9 
variant for binding of substrates containing single mismatches on 
these positions that are opened on the two consecutive positions. 
The binding defects were reversed and the binding constant of 
Cas9_R66A became similar to or even smaller than for Cas9_wt 
on the same mismatched substrate without the bulge (Fig. 5c). The 
gain in binding of Cas9_R66A on opened substrates versus FC 
substrate is less when compared to the gain in binding between 
substrates having a mismatch and opened substrates with the 
same mismatch. Therefore, the decreased binding of Cas9_R66A 
on mismatched substrates containing the bulge is not only due to 
the opening of the DNA. In addition to being important for RNA 
binding, reflected in its interaction with the sgRNA backbone in 
positions that base-pair to target DNA positions 7 and 8 (refs. 28–31), 
these results indicate that R66 has a stabilizing effect on R-loop 
formation in the presence of a mismatch over almost the entire 
seed sequence.
Cas9_R70A binds the target DNA comparably to Cas9_wt, 
but displays a binding defect on substrates with mismatches from 
positions 3–9 (Fig. 4d). However, if the mismatched substrate is 
followed by a bulge, Cas9_R70A can bind these substrates equally 
or better than Cas9_wt (Fig. 5d). This indicates that R70, which 
interacts with the sgRNA backbone in positions that base pair to 
target DNA positions 6 and 7 (refs. 28–31), has a stabilizing effect 
on the R-loop in the presence of mismatches from positions 3–7, 
similar to Cas9_R66A (Fig. 5c).
Cas9_R63A/Q768A is an enhanced specificity Cas9 variant. 
Replacing R63 or R66 with alanine increases Cas9 sensitivity to 
mismatches in the PAM-adjacent part of the target, whereas muta-
tion Q768A increases sensitivity to PAM-distal mismatches. To 
assess whether Cas9 variants with a combination of these changed 
residues have an additive effect on specificity, we determined the 
in  vitro cleavage rates of Cas9_R63A/Q768A and Cas9_R66A/
Q768A (Supplementary Fig. 11a,b), and tested them also in the 
bacterial survival assays (Supplementary Fig. 11c,d). Both Cas9 
variants were sensitive to mismatches in most positions of the tar-
get in vitro and in bacterial cells, as both showed reduced cleavage 
rates and increased survival compared to the WT targets 
(Supplementary Fig. 11).
Cas9_R63A/Q768A shows enhanced gene editing specificity. In 
addition, we tested Cas9_R63A/Q768A and Cas9_R66A/Q768A for 
gene editing activity in the human cell line MCF-7 (Supplementary 
Table 5) with four sgRNAs targeting EpCAM. We used flow cytometry 
to determine the fraction of EpCAMpositive versus EpCAMnegative 
cells (Supplementary Fig. 12) as read-out for editing efficiency. 
Cas9_R63A/Q768A showed activity, although lower than Cas9_wt 
(Fig. 6a), whereas Cas9_R66A/Q768A did not exhibit any editing 
activity (Supplementary Fig. 13). To examine whether Cas9_R63A/
Q768A is more sensitive to mismatches than Cas9_wt, we repeated 
the experiment with sgRNAs EpCAM-1 and EpCAM-4, contain-
ing a mismatch in different PAM-distal positions (Supplementary 
Fig. 14). Cas9_R63A/Q768A showed increased specificity in a 
sgRNA dependent manner. With sgRNA EpCAM-4, Cas9_R63A/
Q768A was more sensitive to most PAM-distal mismatches when 
compared to Cas9_wt (Fig. 6b). Cas9_R63A/Q768A shows no 
editing in the presence of a mismatch in position 15, in agreement 
with the results obtained in vitro and in bacteria (Supplementary 
Fig. 11). With sgRNA EpCAM-1 we observed minimal to no editing 
for positions 14 and 16–19, probably due to a difference in the on-
target activity between Cas9_wt and the mutant. Considering this, 
Cas9_R63A/Q768A was significantly more specific than Cas9_wt 
only on position 13 (Fig. 6c).
Finally, we performed gene editing experiments in human 
embryonic kidney 293 (HEK293) cells with two sgRNAs targeting 
VEGFA and one sgRNA targeting EMX1 with previously charac-
terized off-target sites33. On- and off-target sites (Supplementary 
Table 6) from Cas9-treated cells were analyzed by amplicon 
sequencing (Fig. 6d–f). Cas9_R63A/Q768A cleaved the on-target 
sites with all three guides with similar (VEGFA3 and EMX1.4) or 
lower (VEGFA1) efficiency than Cas9_wt. Cas9_R63A/Q768A 
showed significantly higher specificity at off-target sites compared 
to Cas9_wt, except with sgRNA targeting EMX1 (Fig. 6d–f).
Discussion
Designing highly specific Cas9 variants that do not cleave off-targets 
is crucial for genome editing. Considering their natural function 
as defense systems against invading nucleic acids, Cas9 enzymes 
evolved to tolerate certain mismatches to be able to cleave viral escape 
mutants34,35. Cas9 is sensitive to mismatches in the PAM-adjacent 
and PAM-distal part of the target, but shows flexibility toward 
mismatches in the middle of the target2. Here, we show that a mis-
match at position 15 causes hyperactivity of Cas9 in  vitro and in 
bacteria, but not in human cells. This hyperactivation is depen-
dent on Q768 given that it is no longer observed when Q768 was 
exchanged. How Q768 is involved in the hyperactivation of Cas9 is 
not yet understood. Given its distance from the RNA–DNA hybrid, 
the effect is most probably indirect (Fig. 2a). Therefore, other res-
idues in closer proximity to target DNA position 15 might be of 
interest for future studies. Enhanced cleavage in presence of this 
mismatch was also detected with Cas9 of S. mutans (Supplementary 
Fig. 4), indicating that it may be a common feature of some type 
II-A Cas9 proteins.
Structural and biochemical characterization of Cas9 led to the 
identification of several domains responsible for sgRNA and DNA 
binding (REC lobe), PAM recognition (PI-domain) or DNA cleav-
age (HNH and RuvC domains)2,28–31,36. Here, we analyzed biochemi-
cal properties of Cas9_wt and specific variants in  vitro. It has to 
be noted that due to differences in the experimental setup, kinetic 
parameters for Cas9_wt differ from previously published ones for 
dCas9 (ref. 4), namely 0.49 nM versus 35.5 nM. These differences 
include the nature of the protein (Cas9_wt versus dCas9), the sub-
strate length for DNA binding assays (55 bp versus 90 bp), prepa-
ration of the substrates (annealed oligos versus gel purified PCR 
products), concentration of dual-RNA used (either 1 or 10 M excess 
of dual-RNA over Cas9 versus 2 M excess), presence and nature 
of a competitor, differences in Cas9 purification, reaction time 
and so on.
We determined all values using the same setup for all Cas9 vari-
ants, which only serve as a measure of comparison to analyze the 
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influence of investigated Cas9 residues on RNA or DNA binding and 
cleavage. We were also able to confirm the in vitro results in bacteria 
and human cells. The in vitro analysis showed that the bridge helix 
arginines are involved in RNA and target DNA binding or catalysis 
and most importantly in mismatch sensing and R-loop stabilization. 
These arginines can be separated into two groups. First, R69, R71, 
R74 and R78 were found to confer sensitivity toward mismatches. 
Changing these residues rendered Cas9 more unspecific. Second, 
R63, R66 and R70 confer tolerance to Cas9 in the presence of a mis-
match. Replacement of these residues rendered Cas9 more specific. 
These contrasting observations indicate that these Cas9 residues 
are involved in the balance between specificity and efficiency in the 
natural CRISPR system.
Additionally, R63, R66 and R70 reduce mismatch sensitivity by 
stabilizing the R-loop. Mutation of any one of these residues resulted 
in increased mismatch sensitivity at position 8 for Cas9_R63A or 
along the seed sequence for Cas9_R66A and Cas9_R70A. A bulge 
in the substrate around these positions neutralized this sensitivity 
and led to binding constants comparable to Cas9_wt on the same 
substrate.
According to the kinetic model for the specificity of RNA-
guided nucleases proposed by Bisaria et al.37, it was suggested that 
by increasing the dissociation constant and/or decreasing the cleav-
age rate the rate-limiting step of the reaction can be shifted from 
binding to cleavage. This would increase the time Cas9 has to equili-
brate its binding and could result in preference of on- over off-target 
cleavage37. In accordance with this model, a recent study38 showed 
that R-loop formation is the rate-limiting step, which reduces the 
DNA dissociation rate of Cas9. Replacing R63 and R66 increased 
the dissociation constant and/or decreased the cleavage rate of 
Cas9 by possibly destabilizing the R-loop. Therefore, this model for 
specificity enhancement37 could be a possible explanation for the 
observed increased mismatch sensitivity of our mutants.
The conformational transition of the HNH domain from inac-
tive to the catalytically active state in the other enhanced speci-
ficity Cas9 variants such as eSpCas9 (ref. 17) (mutations in HNH 
and PAM-interacting domains), SpCas9-HF1 (ref. 15) (mutations 
in HNH and REC3 domains) and HypaCas9 (ref. 10) (mutations 
in REC3 domain) was blocked in the presence of PAM-distal 
mismatches. This mechanism is mediated by the REC3 domain10. 
Considering that R63, R66 and Q768 are located in the bridge helix 
and RuvC domain, respectively, a mechanism similar to the one 
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0.013 0.003 1.4 × 10–05 3.7 × 10–05 0.0079
3.1 × 10–04
9.7 × 10–05 0.01 2.1 × 10–04 0.0039
0.0044 0.044 0.021 0.044
0.00970.0210.010.017
0.00970.024
Fig. 6 | Cas9_R63a/Q768a displays enhanced editing specificity in human cells. a, Percentage of EpCAM on-target editing in MCF-7 cells by Cas9_wt 
(dark orange) and Cas9_R63A/Q768A (light orange) in the presence of four different sgRNAs, determined by flow cytometry as described in Methods. 
b,c, Percentage of EpCAM editing by Cas9_wt (dark orange) and Cas9_R63A/Q768A (light orange) in the presence of EpCAM-4 (b) and EpCAM-1 (c) 
sgRNAs, that were either fully complementary to the target site (on-target), or contained the indicated mismatches to the PAM-distal part of the target 
site. Editing percentage was determined by flow cytometry as described in Methods. d–f, Percentage of on- and off-target editing in HEK293 cells by 
Cas9_wt (dark orange) and Cas9_R63A/Q768A (light orange) with sgRNAs targeting VEGFA3 (d), VEGFA1 (e) and EMX1.4 (f) sites, determined by 
amplicon sequencing with a mean coverage of 64,000 paired-end reads per library (also see Methods). a–f, OT stands for off-target. Error bars represent 
s.d. (n ≥ 3 independent experiments, Supplementary Table 4). Values from independent replicates are shown as black dots and the center value represents 
the mean. Statistical significance was determined by a two-sided standard t-test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, exact values are 
shown below the asterisks).
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The trade-off between on-target activity and improved specific-
ity might sometimes be disadvantageous as demonstrated by the 
double mutants Cas9_R66A/Q768A and Cas9_RR63,66AA. The 
first is more specific in  vitro and bacteria, but was not active in 
human cells. The second showed an increased specificity in vitro, 
but is inactive in vivo.
Combination of Q768A, which increases Cas9 specificity at 
the PAM-distal part, with a replacement of R63 led to an overall 
improved specificity of Cas9 in vitro and in bacteria, and also dis-
played increased specificity in human cells. This demonstrates that 
a combination of variants altering the kinetic properties and vari-
ants derived from structure-guided analysis is a viable approach to 
optimize Cas9 specificity and provides a basis for further develop-
ment of highly specific Cas9 enzymes.
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Methods
DNA handling. Plasmid DNA preparation (QIAprep Spin MiniPrep Kit, Qiagen), 
PCR (Phusion High-Fidelity DNA Polymerase, Thermo Scientific; Taq DNA 
Polymerase, Fermentas), DNA digestion with restriction enzymes (Thermo 
Scientific or New England Biolabs), DNA ligation (T4 DNA ligase, Fermentas), 
purification of PCR products (QIAquick PCR Purification Kit, Qiagen), gel 
extraction (QIAquick Gel Extraction Kit) and gel electrophoresis were done 
according to the manufacturer’s instructions or using standard protocols39. Site-
directed mutagenesis was done following the PCR-based protocol40. All constructed 
plasmids used in this study were validated by sequencing (LGC Genomics and 
SeqLab) and are listed in Supplementary Table 7. All oligonucleotides (Sigma-
Aldrich and Biomers) used in this study are listed in Supplementary Table 8.
Construction of plasmids for kinetic cleavage assays. Oligonucleotides 
containing the NGG PAM and wt or mutant speM target site (OLEC2286-
OLEC2341) were annealed to generate the double-stranded insert. This was cloned 
using T4 DNA ligase (ThermoFisher) into the beta-galactosidase-encoding gene of 
pEC286, which was digested with Eco91I. The ligation products were transformed 
in E. coli and positive clones were selected by blue-white screening41,42.
Construction of plasmids for the bacterial survival assay. The rfp gene was 
PCR-amplified from pEC1217 using primers containing XbaI and EcoRI 
restriction sites, and cloned into the corresponding sites of the plasmid pStaby1.2 
(Delphi Genetics). Plasmids encoding nuclease-inactive Cas9 (pEC1215) or 
the rfp targeting sgRNA (pEC1218) were obtained from a previously published 
study43. The gene encoding Cas9_wt was PCR-amplified from pEC626 (ref. 44) 
using primers containing SpeI and EagI restriction sites, and cloned into the 
corresponding sites of pEC1215. All Cas9 mutants were generated by site-directed 
mutagenesis of the Cas9_wt-encoding plasmid. To generate plasmids encoding 
sgRNA with single mismatches in each position of the spacer sequence, site-
directed mutagenesis was performed using the appropriate mutation-introducing 
forward primer and OLEC6032 as the reverse primer. Resulting plasmids 
(pEC1537-1556) express sgRNA under control of the J23119 promoter45. To reduce 
the amount of sgRNA expressed, the promoter was mutagenized with OLEC3908 
and OLEC3909 to a weaker version called J23100 (http://parts.igem.org).
Construction of plasmids for in vivo gene editing in eukaryotic cells. 
Oligonucleotides containing sgRNA spacers (OLEC10121-10132, OLEC10341-
10479) targeting the EpCAM gene (fully complementary or with single 
point mutations that caused a mismatch to the target DNA sequence) were 
phosphorylated with T4 polynucleotide kinase (Fermentas) and annealed to 
generate the double-stranded inserts. To obtain the variants Cas9_R63A/Q768A 
and Cas9_R66A/Q768A, site-directed mutagenesis was performed on the plasmid 
pCROPseq_Cas9_wt, which is based on CROPseq-Guide-Puro (Addgene no. 
86708)46 with an added human codon optimized SpCas9 containing a C-terminal 
NLS tag. Cas9-encoding plasmids were digested with Esp3I (Thermo Scientific) 
and dephosphorylated with alkaline phosphatase (Thermo Scientific).
For cloning of sgRNAs containing spacers targeting the VEGFA sites 1 and 3,  
and the EMX1 target site 4, Cas9-encoding plasmids were digested with BpiI 
FD (ThermoFisher) and purified (GeneJET Gel Extraction Kit, ThermoFisher) 
following the manufacturer’s instructions. Oligonucleotides containing sgRNAs 
(CR3373-3378) were mixed and annealed. The inserts were cloned into the 
digested vectors to generate full sgRNAs expressed under the control of  
the U6 promoter.
Preparation of ultra-competent E. coli. Ultra-competent E. coli cells for bacterial 
survival assays were prepared according to refs. 47,48. Bacteria were grown in LB 
medium at 37 °C with 180 r.p.m. and shaking for 6–8 h. This preculture was used 
to inoculate SOB medium (0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2,10 mM MgSO4), in a ratio of 1:200, and grown at 18 °C with 
180 r.p.m. and shaking overnight, until an optical density (OD600nm) of 0.55 was 
reached. The cells were chilled on ice for 10 min and centrifuged at 5,915g for 
10 min at 4 °C. The supernatant was removed, cells were resuspended in ice-cold 
transformation buffer (10 mM HEPES pH 6.7, 15 mM CaCl2, 250 mM KCl, 55 mM 
MnCl2) and incubated for 10 min on ice. The procedure was repeated and 7.5% of 
DMSO was added to the resuspended cells. The cells were incubated for 10 min on 
ice and the aliquots were frozen in liquid nitrogen.
For transformation, cells mixed with 50 ng plasmid DNA were incubated for 
30 min on ice, subjected to heat-shock at 42 °C for 45 s, after which they were 
shortly put on ice. SOC medium (0.5% yeast extract, 2% tryptone, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) was added and 
cells were recovered for 1 h at 37 °C shaking. After recovery, cells were shortly 
centrifuged for 1 min at 6,000 r.p.m. and plated on LB agar plates with  
50 µg ml−1 streptomycin, 100 µg ml−1 carbenicillin, 30 µg ml−1 chloramphenicol  
and 1% glucose.
RNA in vitro transcription. All RNAs used in the in vitro assays were in vitro 
transcribed with the AmpliScribe-T7 Flash Transcription kit (Epicentre) according 
to manufacturer’s instructions. The templates for the reaction were either synthetic 
oligonucleotides or generated by PCR (listed in the Supplementary Table 8). 
In vitro transcribed RNAs were purified as described previously44. Equimolar 
amounts of tracrRNA and crRNA were annealed in 5× RNA annealing buffer 
(1 M NaCl, 100 mM HEPES, pH 7.5) at 95 °C for 5 min, and slowly cooled to room 
temperature.
Cas9 protein purification. E. coli NiCo21 (DE3) competent cells (New England 
Biolabs) (Supplementary Table 9) were transformed with overexpression plasmids 
encoding WT or mutant Cas9. Protein overexpression and purification by  
Ni-NTA affinity chromatography was performed as previously described44. 
Protein containing fractions were further purified over chitin beads (New England 
Biolabs), as in ref. 44, and dialyzed against dialysis buffer (20 mM HEPES pH 7.5, 
150 mM KCl, 50% glycerol). Protein concentration was determined using the 
Bradford assay and nucleic acid contamination was assessed by measuring  
the A260/A280 ratio.
Generation of substrates for electrophoretic mobility shift assays (EMSAs). 
Substrates used for EMSAs were generated by PCR or from synthetic 
oligonucleotides (Sigma-Aldrich). In the first case, the target sequence (wt or 
mutated protospacer 2, speM) was amplified from plasmids (pEC576-pEC599) 
using primers OLEC4816 and OLEC4817. Products were precipitated with sodium 
acetate and ethanol, and purified over a 1.5% agarose gel in 1× TBE buffer (0.1 M 
Tris, 0.1 M boric acid, 0.002 M EDTA). The corresponding bands were excised from 
the gel and the DNA was isolated using the QIAquick Gel Extraction Kit (Qiagen).
In the second case, HPLC-purified synthetic oligonucleotides containing 
the target sequence were used. To generate a double-stranded EMSA substrate, 
oligonucleotides containing the target and nontarget DNA strand were annealed in 
5× RNA annealing buffer at 95 °C for 5 min and left at room temperature for slow 
cooling. The substrates were purified over 6% polyacrylamide gel in 1× TBE buffer 
and the corresponding bands were excised. Gel pieces containing the samples were 
incubated overnight at 4 °C in 1× TE buffer (1 M Tris-HCl pH 8, 0.5 M EDTA) and 
afterward DNA was precipitated with sodium acetate and ethanol. Reactions were 
centrifuged for 30 min at 15,000g and DNA pellets were resuspended in MQ water. 
The concentration of the DNA was determined by measuring the absorbance at 
260 nm with NanoDrop (Thermo Fisher Scientific).
EMSAs. Substrates for EMSAs were radiolabeled with [ɣ-32P]-ATP (Hartmann 
Analytics) using T4 polynucleotide kinase (Fermentas) and purified on Illustra 
Microspin G-25 columns (GE Healthcare). Binding reactions with increasing 
concentrations of wt or mutant Cas9 and a 2× molar excess of dual-RNA over 
protein were preincubated in Binding buffer (20 mM Tris-HCl pH 7.5, 100 mM 
KCl, 5 mM CaCl2·2H2O, 5% glycerol, 1 mM DTT) or KG buffer (100 mM 
potassium glutamate, 25 mM Tris-acetate pH 7.5, 10 mM Mg-acetate, 0.5 mM 
2-mercaptoethanol, 10 mg ml−1 bovine serum albumin)49, for 15 min at 37 °C, 
before the addition of 1 nM labeled substrates. After addition of DNA, binding 
reactions took place at 37 °C for 1 h. Protein–DNA complexes were separated 
by 5% native polyacrylamide gel electrophoresis in 0.5× TBE buffer with 5 mM 
CaCl2·2H2O. The gels were exposed on autoradiography film overnight and 
visualized by phosphorimaging. Results of at least three independent experiments 
were quantified with Gel Analyzer (http://www.gelanalyzer.com/index.html) 
and the binding constants were determined by fitting to the Hill’s equation 
yb ¼ Vmax ´ xnC= kn þ xnC
 
I
 (yb, % of bound DNA; xC, enzyme concentration (nM); 
Vmax, maximally bound DNA; k, KD; and n, Hill coefficient) using Origin Software 
(OriginLab).
RNA-binding assays. Purified WT or variant Cas9 proteins were labeled with the 
NT-647-His labeling fluorescent dye (NanoTemper Technologies) in 1× PBST 
buffer (NanoTemper Technologies) according to the manufacturer’s instructions. 
Labeled Cas9 was incubated with increasing concentrations of dual-RNA in RNA 
Binding buffer (20 mM Tris-HCl pH 7.5, 100 mM KCl, 5 mM CaCl2·2H2O, 5% 
glycerol, 1 mM DTT, 0.05% Tween-20). To remove potential aggregates, reactions 
were centrifuged before loading into the Monolith NT.115 MST Premium Coated 
Capillaries (NanoTemper Technologies). Binding of Cas9 to dual-RNA was 
measured by microscale thermophoresis using the NanoTemper Monolith NT.115. 
Binding constants were determined by fitting data from at least three independent 
experiments to the exponential binding equation using the MO Affinity Analysis 
Software (NanoTemper Technologies).
Kinetic cleavage assays. Dual-RNA (20 nM) and Wt or mutant Cas9 (10 nM)  
were preincubated for 15 min at 37 °C in KG buffer. For kinetic cleavage assays  
with S. mutans Cas9, 50 nM dual-RNA and 25 nM Cas9 were used. Plasmids 
containing WT or mutated target sequence (pEC576-599) were added to a final 
concentration of 5 nM and incubated for 90 min at 37 °C. At defined time points 
(1, 2, 5, 10, 20, 40, 60 and 90 min) samples were withdrawn and the reaction was 
stopped by addition of 5× loading buffer (250 mM EDTA, 30% glycerol, 1.2%  
SDS, 0.1% bromophenol blue). Cleavage products were resolved by 1% agarose  
gel electrophoresis in 1× TAE buffer (0.04 M Tris, 0.02 M acetic acid, 1 mM  
EDTA). DNA was visualized by ethidium bromide staining. Band intensity of  
open circular, linear and supercoiled DNA was analyzed by densitometry using  
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Image Lab software (Bio-Rad Laboratories, Inc.). Data obtained from at least  
three independent experiments were fitted to the equations stated below in  
Origin Software (OriginLab). The rate of disappearance of the supercoiled plasmid 
DNA (k1obs) was calculated using ysc ¼ ysc0þ Asc ´ exp �k1 ´ xbð Þ
I
 (ysc, amount 
of supercoiled DNA; ysc0, amount of supercoiled DNA at infinite time 0; Asc, 
maximal amount of supercoiled DNA that was cleaved; k1, k1obs; xt, time in min). 
The rate of appearance of the linear plasmid DNA (k2obs) was calculated using: 
yli ¼ yli0þ Ali ´ 1� exp �k2 ´ xtð Þð Þ
I
 (yli, amount of linear DNA; yli0, amount of 
linear DNA at infinite time 0; Ali, maximal amount of linear DNA after cleavage; 
k2, k2obs; and xt, time in min).
Kinetic cleavage assays on linear substrates were performed on oligonucleotides 
containing the NGG PAM and speM target site (WT or with mismatches in 
positions 10–14), with either the target or nontarget strand radioactively labeled 
as described above. Equimolar amounts of labeled and nonlabeled substrate 
were annealed at 95 °C and slowly cooled to room temperature. Double-stranded 
substrates were purified with DNA Clean & Concentrator −5 (Zymo Research). 
Kinetic cleavage assays were performed as described using 2 nM radioactively 
labeled DNA substrates, 7.5 nM Cas9 and 15 nM dual-RNA. Reactions were 
stopped by the addition of 2× loading buffer (95% formamide, 0.025% SDS, 25 mM 
EDTA, 0.025% bromophenol blue) and incubated for 5 min at 95 °C, before loading 
on a 12% PAA-urea gel. The gels were exposed on autoradiography film overnight 
and visualized by phosphorimaging.
Bacterial survival assay. The bacterial survival assay is based on a three-plasmid 
system (Supplementary Fig. 1). The three plasmids encoding red fluorescent 
protein (RFP), Cas9 and sgRNA, respectively, are based on a previously published 
system43. Cas9 is expressed under control of the arabinose promoter, the sgRNA 
targeting the 5′ region of rfp is constitutively expressed by the J23100 promoter 
and RFP expression is controlled by T7 promoter and lacO operator. The bacterial 
cells used in the assay are E. coli SE4 (Delphi genetics), an engineered derivative 
of BL21DE3, additionally encoding the toxin CcdB (Supplementary Table 9). The 
corresponding antitoxin CcdA is encoded on the RFP expressing plasmid. E. coli 
SE4 was transformed with these three plasmids in a consecutive manner. In short, 
plasmid encoding RFP (pEC2132) was transformed using a standard heat-shock 
transformation protocol39. The resulting clones were made ultra-competent as 
described above. pEC2132-containing ultra-competent cells were transformed 
with plasmids encoding WT sgRNA or sgRNA with single mismatches in the 
spacer (pEC2013 and pEC2052-2071), and the resulting cells were made ultra-
competent again. Finally, SE4 cells that contained the RFP-encoding plasmid and 
the sgRNA-encoding plasmid were transformed with 50 ng plasmid encoding 
Cas9_wt or mutant Cas9 proteins. The complete transformation mix was plated 
on LB agar plates containing 50 µg ml−1 streptomycin, 100 µg ml−1 carbenicillin, 
30 µg ml−1 chloramphenicol and 1% glucose. The concentration of the antibiotics 
was kept constant throughout the experiment. The next day, individual colonies 
(2–3) were used to inoculate 2 ml of LB medium with the addition of streptomycin, 
carbenicillin, chloramphenicol and 1% glucose, and grown at 37 °C for 6.5 h with 
shaking at 180 r.p.m. The OD600 nm was measured using a plate reader (BioTek) 
and the appropriate volume of each culture was taken to normalize the OD600nm 
to 0.03. Samples were centrifuged for 1 min at 6,000 r.p.m., the supernatant was 
removed and the pellet was resuspended in 100 µl LB medium with streptomycin, 
carbenicillin and chloramphenicol. Then, 2 µl of each sample was added to the  
96-well plate containing 198 µl of either LB medium with streptomycin, 
carbenicillin, chloramphenicol and 1% glucose (suppressing conditions), or  
LB medium with streptomycin, carbenicillin, chloramphenicol, 33 mM arabinose 
and 0.1 mM IPTG (inducing conditions).
Under suppressing conditions, neither RFP nor Cas9 is expressed and 
CcdB is neutralized by the presence of CcdA. Under inducing conditions three 
scenarios are possible. (1) Cas9 is cleavage and binding deficient. RFP and 
CcdA are expressed, the cells grow and fluorescence can be detected. (2) Cas9 is 
cleavage deficient, but able to bind its target site. The cells grow since CcdA is still 
expressed, but rfp expression is repressed by Cas9 binding to the 5′ region of the 
gene. (3) Cas9 is able to bind and cleave the RFP and CcdA encoding plasmid. 
This leads to death of the cells, since the CcdA antitoxin is no longer expressed 
and cannot neutralize the toxin CcdB. To distinguish between these scenarios, 
the OD600nm and red fluorescence units (excitation wavelength 555 nm, emission 
wavelength 588 nm) were measured with a fluorescence plate reader (Biotek) in 
5-min intervals during a 10 h kinetic experiment, at 37 °C with shaking. After 
subtraction of the blank samples, survival was calculated by dividing the OD600nm at 
inducing conditions by the OD600nm at suppressing conditions. Statistical analysis of 
at least five replicates was performed using Origin Software (OriginLab).
Human cell culture and transfections. MCF-7 cells (Supplementary Table 5) 
were cultured at 37 °C with 5% CO2 in advanced DMEM (Thermo Scientific) 
supplemented with 10% heat-inactivated fetal bovine serum (Thermo Scientific), 
2 mM GlutaMax (Thermo Scientific) and penicillin-streptomycin (Sigma-Aldrich). 
HEK293 cells (Supplementary Table 5) were cultured at 37 °C with 5% CO2 in 
DMEM (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Gibco), 
2 mM l-glutamine (Sigma-Aldrich) and Normocin (Invivogen).
Cells were seeded in six-well or 24-well plates 24 h before transfection at a 
density of 100,000 cells per ml. Transfections of plasmids with sgRNAs targeting 
EpCAM were performed with the jetPRIME transfection reagent (Polyplus) 
according to the manufacturer’s instructions. MCF-7 cells were transfected with 
500 ng of plasmid DNA. Transfected cells were selected by adding 2 µg ml−1 
of puromycin (Sigma-Aldrich) 1 d after transfection. Growth medium with 
puromycin was replaced by standard growth medium after 2 d. Cells were analyzed 
by flow cytometry 8–10 d post transfection.
HEK293 cells were transfected with 1 µg plasmids p1490-1492, p1498-1500  
in 24-well plates using Lipofectamine 3000 (Invitrogen) according to the 
manufacturer’s protocol. Transfected cells were selected with 1 µg ml−1 puromycin 
(Invivogen) for 3 d starting at day 1 post transfection. Cells were collected 5 d 
post transfection and lysed with the DirectPCR Lysis Reagent (Cell) (Viagen), 
supplemented with Proteinase K (ThermoFisher) according to the manufacturer’s 
protocol. Genomic DNA extracted from these cells was used for PCR amplification 
of on- and off-target sites and amplicon sequencing.
Flow cytometry. To determine the levels of EpCAM editing by Cas9_wt, 
Cas9_R63A/Q768A and Cas9_R66A/Q768A, cells were stained with human 
EpCAM (CD326) antibody conjugated to FITC (Miltenyi Biotec) according to the 
manufacturer’s instructions. Dead cells were excluded from the analysis by staining 
with the 7-AAD viability staining solution (BioLegend). Samples were acquired 
with the Sony SH800 cell sorter and data were analyzed with the FlowJo software 
v.10.5.3 (Tree Star).
Amplicon sequencing. On-target and off-target sites were PCR-amplified with 
Phusion High-Fidelity DNA Polymerase (Thermo Scientific) using primers listed 
in Supplementary Table 8. The following PCR program was used: (98 °C, 10 s; 
appropriate annealing temperature for each primer pair, 15 s; 72 °C, 30 s) × 35 cycles 
(30 cycles for nested PCRs), with the addition of DMSO if necessary. Libraries 
were prepared with 10 ng DNA for each sample using the KAPA HyperPrep-Kit 
(Roche), according to the manufacturer’s instructions, without fragmentation and 
size selection. This was followed by eight cycles of PCR to add sequencing adapters. 
After quality control, libraries with similar size were pooled together, resulting in 
four pools of 14 libraries, respectively one pool of 20 libraries. These pools were 
quantified with the KAPA Library Quantification Kit (Roche), normalized to 2 nM 
and pooled again equimolarly to load them on the MiSeq.
Fastq data was analyzed using the ampliCan50 pipeline with the following 
parameters: fastqfiles=0.5, average_quality=30, min_quality=0. Briefly, each read 
was subjected to quality control, requiring an average base call quality greater than 
30, and no ambiguous nucleotides. Filtered reads were aligned via Needleman–
Wunsch algorithm to their expected amplicon sequence, given their flanking 
primers, as extracted from human genome reference GRCh38. The results of the 
ampliCan pipeline were tallied and reported as the total edited and frameshift 
indels divided by the number of filtered reads passing quality control.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated and analyzed during this study are available from the 
corresponding author upon request. Raw pictures for all in vitro experiments are 
available as Supplementary Note 1 online. Amplicon sequencing data are available 
online (accession code PRJNA577558).
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